<SEC-DOCUMENT>0001193125-18-266272.txt : 20180904
<SEC-HEADER>0001193125-18-266272.hdr.sgml : 20180904
<ACCEPTANCE-DATETIME>20180904163805
ACCESSION NUMBER:		0001193125-18-266272
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180831
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180904
DATE AS OF CHANGE:		20180904

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MEDNAX, INC.
		CENTRAL INDEX KEY:			0000893949
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOSPITALS [8060]
		IRS NUMBER:				263667538
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12111
		FILM NUMBER:		181052772

	BUSINESS ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323
		BUSINESS PHONE:		9543840175

	MAIL ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PEDIATRIX MEDICAL GROUP INC
		DATE OF NAME CHANGE:	19950801
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d618209d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (date of earliest event reported): August&nbsp;31, 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MEDNAX, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
Name of Registrant as Specified in Its Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Florida</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-12111</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">26-3667538</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1301 Concord Terrace </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sunrise, Florida 33323 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) (zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code (954) <FONT STYLE="white-space:nowrap">384-0175</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this
chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;1.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Entry into a Material Definitive Agreement. </B></P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.03</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Creation of a Direct Financial Obligation or an Obligation under an
<FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangement of a Registrant. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;31, 2018, MEDNAX, Inc., a
Florida corporation (the &#147;Company&#148;), entered into an uncollared accelerated share repurchase (&#147;ASR&#148;) agreement with Bank of America, N.A. (&#147;Bank of America&#148;), to repurchase $250&nbsp;million of the Company&#146;s common
stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the ASR agreement, the Company made a $250&nbsp;million payment to Bank of America and received an aggregate delivery of
4.2&nbsp;million shares of the Company&#146;s common stock on September&nbsp;4, 2018. The final number of shares to be repurchased will be based on the volume-weighted average share price of the Company&#146;s common stock during the term of the ASR
agreement, minus a discount and subject to adjustments pursuant to the terms and conditions of the ASR agreement. At settlement, under certain circumstances, Bank of America may be required to deliver additional shares of common stock to the Company
or the Company may be required to deliver shares of its common stock or to make a cash payment, at its election, to Bank of America. The final settlement of the transaction under the ASR agreement is expected to occur within six months. The Company
is funding the ASR with borrowings under its existing $2.0&nbsp;billion unsecured revolving credit facility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ASR agreement contains customary terms
for these types of transactions, including, but not limited to, the mechanisms to determine the number of shares or the amount of cash that will be delivered at settlement, the required timing of delivery of the shares, the specific circumstances
under which adjustments may be made to the transactions, the specific circumstances under which the transaction may be terminated prior to its scheduled maturity and various acknowledgements, representations and warranties made by the Company and
Bank of America. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ASR is being executed as part of an authorization by the Company&#146;s Board of Directors to repurchase up to $500&nbsp;million of
the Company&#146;s common stock, announced on August&nbsp;2, 2018. The $500&nbsp;million authorization is incremental to the Company&#146;s existing authorization to repurchase its common stock up to an amount sufficient to offset the dilutive
impact from the issuance of shares under the Company&#146;s equity programs. The Company will continue to contemplate various methods to effect future share repurchases, including, among others, open market purchases and additional accelerated share
repurchase programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, Bank of America and/or its affiliates have directly and indirectly engaged, and may engage in the future, in
transactions with the Company for which they have received, or may receive, customary compensation, fees and expense reimbursement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Regulation FD Disclosure. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;4, 2018, the Company issued a press release announcing its entry into the ASR agreement. A copy of the press release is attached hereto as
Exhibit 99.1 and is hereby incorporated in this Current Report by reference. The information contained in this Item 7.01, including exhibit 99.1, shall not be deemed &#147;filed&#148; with the Securities and Exchange Commission nor incorporated by
reference in any registration statement or other document filed by the Company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>(d)&nbsp;Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">99.1&#151;<A HREF="d618209dex991.htm">Press Release of MEDNAX, Inc. dated September&nbsp;4, 2018. </A> </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d618209dex991.htm">Press Release of MEDNAX, Inc. dated September&nbsp;4, 2018. </A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>MEDNAX, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: September&nbsp;4, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Vivian Lopez-Blanco</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vivian Lopez-Blanco</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Financial
Officer</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d618209dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g618209g0904185614077.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FOR MORE INFORMATION: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charles Lynch </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Strategy and Investor Relations
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">954-384-0175,</FONT></FONT> <FONT STYLE="white-space:nowrap">x-5692</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>charles_lynch@mednax.com </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>FOR IMMEDIATE RELEASE
</U></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEDNAX Commences $250 Million Accelerated Share Repurchase Program </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FORT LAUDERDALE, Fla., September&nbsp;4, 2018 &#150; MEDNAX, Inc. (NYSE: MD), the national medical group specializing in neonatology, anesthesiology,
radiology, maternal-fetal medicine, other pediatric services, and management services, today announced the commencement of a $250&nbsp;million accelerated share repurchase (ASR) program with Bank of America, N.A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the ASR, MEDNAX will repurchase $250&nbsp;million of its common stock, with an aggregate initial delivery of approximately 4.2&nbsp;million
shares. The final number of shares to be repurchased will be based on the volume-weighted average share price of the Company&#146;s common stock during the term of the ASR, minus a discount. The final settlement of the transactions under the ASR
agreement is expected to occur in up to six months. The Company is funding the ASR with borrowings under its credit facility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ASR program is being
executed as part of an authorization by MEDNAX&#146;s Board of Directors to repurchase up to $500&nbsp;million of the Company&#146;s common stock, announced on August&nbsp;2, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The $500&nbsp;million authorization is incremental to the Company&#146;s existing authorization to repurchase its common stock up to an amount sufficient to
offset the dilutive impact from the issuance of shares under MEDNAX&#146;s equity programs. MEDNAX will continue to contemplate various methods to effect future share repurchases, including, among others, open-market purchases and additional
accelerated share repurchase programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ABOUT MEDNAX </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEDNAX, Inc. is a national health solutions partner comprised of the nation&#146;s leading providers of physician services. Physicians and advanced
practitioners practicing as part of MEDNAX are reshaping the delivery of care within their specialties and subspecialties, using evidence-based tools, continuous quality initiatives, clinical research and telemedicine to enhance patient outcomes and
provide high-quality, cost-effective care. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company was founded in 1979, and today, through its affiliated professional corporations, MEDNAX
provides services through a network of more than 4,100 physicians in all 50 states and Puerto Rico. In addition to its national physician network, MEDNAX provides services to healthcare facilities and physicians in over 40 states through two
complementary businesses, consisting of a management services company and a consulting services company. Additional information is available at www.mednax.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Certain statements and information in
this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities
Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to MEDNAX&#146;s objectives, plans and strategies, and all statements, other than statements of historical facts, that address
activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as &#147;believe&#148;, &#147;hope&#148;, &#147;may&#148;,
&#147;anticipate&#148;, &#147;should&#148;, &#147;intend&#148;, &#147;plan&#148;, &#147;will&#148;, &#147;expect&#148;, &#147;estimate&#148;, &#147;project&#148;, &#147;positioned&#148;, &#147;strategy&#148; and similar expressions, and are based on
assumptions and assessments made by MEDNAX&#146;s management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any
forward-looking statements in this press release are made as of the date hereof, and MEDNAX undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements
are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in
MEDNAX&#146;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and its Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> including the sections entitled &#147;Risk Factors&#148;, as well
MEDNAX&#146;s current reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed with the Securities and Exchange Commission. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g618209g0904185614077.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g618209g0904185614077.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !H 7,# 2(  A$! Q$!_\0
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M^@K??^!+_P"-4<CUH_&CE0<S+W]M:M_T%;[_ ,"7_P :/[:U;_H*WW_@2_\
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M7_T ;W_OV:^LJ*ZHXJ48I6.:6&C*3=SP;X2^%==TCQPMUJ&E7-M +:1?,D3
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M& D:X%<Y\2["[U/P+?6EC;O/</MVQH,D\UUM%8QDU*YLXW5CY-_X0+Q7_P!
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M/7BN=\517,_B[P_':7(MIRLVV4IN"\#M72:5;W]M;,FH7RWDI;(=8PF!Z8H
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MCD4E5(P<CM]:X*2?6K6\\43Z7Y!B2X)F#*3)C')7MP*[/PO;6EKX=LTLIC-
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MWLPZPLY<(S9"D]<>@HHH 6?2[6YU.UU"16-Q;!EC(;@!NO%7& 92IZ$8-%%
M%.RTJTT_3!IT*$VP##8YW9!SG/YU'H^B6.A6SV]@C)&[ER&8MS_D444 5-3\
M*:9JM^;VX^T+.4"%HIF3@?2M'3=/@TNR2TMS(8T)(,CEVY.>IHHH 99Z39V+
LWC0H?],E,LP8Y#,>#^%&E:5;:-9_9+/>( Q95=RVW/8>WM110!>HHHH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
